Ligands MCP-4, MCP-3, RANTES, MCP-2, MCP-1 or eotaxin, has been identified for the G-protein receptor HGBER32.

The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3.

Novel antagonists of MCP proteins, in particular of MCP-1 protein, can be obtained by generating MCP mutants whose GAG binding site, located at the N- terminal of MCP proteins, is eliminated following non-conservative substitutions.

Individual LCM and panels comprising multiple LCM are provided for these and other uses.

The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3.

Substantially pure nucleic acid molecules encoding the monocyte chemotactic proteins MCP-4 and MCP-5.

The claimed MCP-1 derivatives can be administered to a patient in need of inhibiting MCP-1 monocyte chemoattractant activity.

The compositions of the invention include an antagonist of MCP-1 and/or CCR2 that blocks MCP-1 binding to or activation of CCR2y.

In particular embodiments, the expression or activity of MyD88, CCR2, MCP-I or MCP-3 is targeted.

The MCP of the invention affords the ability to deliver a concentrated radionuclide mass to a target cell by coupling the MCP to a targeting agent.

Moreover, the MCP cells are non-contracting.

Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE) are described.

Furthermore, the MCP cells have a characteristic morphology.

Molecules and compositions including same for the isolation of MCP-1 and treatment of CCR2/MCP-1 associated diseases.

MCP joint (third joint from the fingertip) : Osteoarthritis rarely affects the MCP joints.